Effect of Osimertinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma
Objective To observe the effect of osimertinib combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods A total of 80 patients with advanced lung adenocarcinoma admitted from July 2021 to August 2023 were randomly divided into the control group(n=40)and the observation group(n=40).The control group was treated with pemetrexed combined with cisplatin.The observation group was given osimertinib.The clinical efficacy,tumor marker levels,vascular growth factors,adverse reactions and quality of life were compared between the two groups.Results The total effective rate and Karnofsky score in the observation group were higher than those in the control group(P＜0.05).After treatment,the observation group CEA[(8.53±1.37)ng/ml],CA125[(46.71±5.82)U/ml],CYFRA21-1[(11.06±2.08)ng/ml],CA199[(45.83±9.26)U/ml],bFGF[(149.85±18.69)pg/ml],MMP-9[(1 012.47±85.47)ng/ml],VEGF[(230.41±41.87)pg/ml]were lower than those in the control group[(12.73±2.45)ng/ml,(58.47±6.59)U/ml,(14.76±1.85)ng/ml,(51.72±9.58)ng/ml,(176.49±19.54)pg/ml,(1 461.37±96.54)ng/ml,(271.47±48.35)pg/ml](P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group(32.50%)and the control group(25.00%)(P＞0.05).Conclusion For patients with advanced lung adenocarcinoma,the use of on the basis of chemotherapy has obvious effects,can reduce the level of tumor markers and vascular growth factor,improve the quality of life of patients,and has a certain safety.
万方数据
维普
